AI Article Synopsis
- Migraine treatments targeting calcitonin gene-related peptide (CGRP), like monoclonal antibodies and gepants, have good effectiveness and tolerability, but interactions with COVID-19 treatments need exploration.
- The text covers CGRP characteristics, COVID-19 treatments, interactions between CGRP drugs and COVID-19 meds, and possible neurological effects of COVID-19.
- Experts advise caution with gepants in COVID-19 patients due to potential drug interactions, particularly with Paxlovid; however, CGRP monoclonal antibodies have no known interactions and should be spaced from vaccinations to assess side effects.
Article Abstract
Introduction: Migraine pharmacological therapies targeting calcitonin gene-related peptide (CGRP), including monoclonal antibodies and gepants, have shown clinical effect and optimal tolerability. Interactions between treatments of COVID-19 and CGRP-related drugs have not been reviewed.
Areas Covered: An overview of CGRP, a description of the characteristics of each CGRP-related drug and its response predictors, COVID-19 and its treatment, the interactions between CGRP-related drugs and COVID-19 treatment, COVID-19 and vaccination-induced headache, and the neurological consequences of Covid-19.
Expert Opinion: Clinicians should be careful about using gepants for COVID-19 patients, due to the potential drug interactions with drugs metabolized via CYP3A4 cytochrome. In particular, COVID-19 treatment (especially nirmatrelvir packaged with ritonavir, as Paxlovid) should be considered cautiously. It is advisable to stop or adjust the dose (10 mg atogepant when used for episodic migraine) of gepants when using Paxlovid (except for zavegepant). CGRP moncolconal antibodies (CGRP-mAbs) do not have drug - drug interactions, but a few days' interval between a COVID-19 vaccination and the use of CGRP mAbs is recommended to allow the accurate identification of the possible adverse effects, such as injection site reaction. Covid-19- and vaccination-related headache are known to occur. Whether CGRP-related drugs would be of benefit in these circumstances is not yet known.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17425255.2023.2280221 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System.
BioDrugs
March 2024
Department of Clinical and Experimental Medicine, University of Messina, 98125, Messina, Italy.
Introduction: Anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP-mAbs) have recently been approved for the prevention of migraine, and their safety profile is not fully characterized.
Objective: The aim of this study was to evaluate the adverse drug reactions (ADRs) of anti-CGRP-mAbs through the analysis of individual case safety reports (ICSRs) collected in the EudraVigilance (EV) database, with a specific focus on cardiovascular (CV) ADRs.
Methods: Data on ICSRs recorded between July 2018 and December 2022 in the EV database, involving one of the anti-CGRP-mAbs for migraine prevention-erenumab (ERE), galcanezumab (GMB), fremanezumab (FMB), and eptinezumab (EPT)-were included in the analysis.
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review.
Expert Opin Drug Metab Toxicol
December 2023
School of Health Sciences, Unitelma Sapienza University of Rome, Rome, Italy.
Article Synopsis
- Migraine treatments targeting calcitonin gene-related peptide (CGRP), like monoclonal antibodies and gepants, have good effectiveness and tolerability, but interactions with COVID-19 treatments need exploration.
- The text covers CGRP characteristics, COVID-19 treatments, interactions between CGRP drugs and COVID-19 meds, and possible neurological effects of COVID-19.
- Experts advise caution with gepants in COVID-19 patients due to potential drug interactions, particularly with Paxlovid; however, CGRP monoclonal antibodies have no known interactions and should be spaced from vaccinations to assess side effects.
CGRP and migraine: from bench to bedside.
Rev Neurol (Paris)
September 2021
Department of Medicine, University Hospital, 22185 Lund, Sweden. Electronic address:
Migraine treatment has reached a new era with the development of drugs that target the trigeminal neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. The CGRP related therapies offer considerable improvements over existing drugs as they are the first to be designed to act on the trigeminal pain system, more specific and with few adverse events. Small molecule CGRP receptor antagonists, such as rimegepant and ubrogepant, are effective for the acute treatment of migraine headache.
View Article and Find Full Text PDFCalcitonin gene‑related peptide‑mediated pharmacological effects in cardiovascular and gastrointestinal diseases (Review).
Mol Med Rep
January 2021
Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China.
Calcitonin gene‑related peptide (CGRP) is the predominant neurotransmitter located in sensory nerves. This peptide is extensively distributed in central and peripheral tissues. CGRP causes relaxation of cardiovascular smooth muscle cells and confers protection against ischaemic myocardium and cardiac remodeling.
View Article and Find Full Text PDFRole of CGRP in Migraine.
Handb Exp Pharmacol
September 2019
Division of Experimental Vascular Research, Department of Clinical Sciences, Lund University, Lund, Sweden.
Migraine is a common neurological disorder that afflicts up to 15% of the adult population in most countries, with predominance in females. It is characterized by episodic, often disabling headache, photophobia and phonophobia, autonomic symptoms (nausea and vomiting), and in a subgroup an aura in the beginning of the attack. Although still debated, many researchers consider migraine to be a disorder in which CNS dysfunction plays a pivotal role while various parts of the trigeminal system are necessary for the expression of associated symptoms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!